
Vivos Therapeutics (VVOS) Stock Forecast & Price Target
Vivos Therapeutics (VVOS) Analyst Ratings
Bulls say
Vivos Therapeutics Inc. demonstrated a robust financial performance, reporting a 76% year-over-year revenue growth in Q3 FY25, driven substantially by the integration of the SCN model, which has enhanced revenue generation with minimal additional investment. The company's service revenue exceeded $4.6 million, reflecting a significant increase due to contributions from sleep testing and treatment-center revenues associated with the SCN initiative. Additionally, with continued deployment of service organization teams and strong improvements in patient outcomes, Vivos is well-positioned for sustained revenue growth, particularly as market demand is expected to flourish in North America and the fast-growing Asia Pacific region.
Bears say
Vivos Therapeutics Inc. has experienced a year-over-year revenue decline of 9% in the first half of 2025, primarily attributed to its transition to a new sleep center operation model, which has negatively impacted its financial performance. The company's gross margins dwindled to 55% in the second quarter of 2025, driven by discounting strategies and a shift in product and service offerings, indicating potential challenges in cost management. Additionally, persistent operating losses, negative cash flow, and a significant accumulated deficit exemplify the ongoing uncertainty regarding Vivos' ability to achieve sustainable profitability and maintain growth amidst competitive and regulatory pressures.
This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Vivos Therapeutics (VVOS) Analyst Forecast & Price Prediction
Start investing in Vivos Therapeutics (VVOS)
Order type
Buy in
Order amount
Est. shares
0 shares